Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 241.57 as of 2026-10-06T16:41:33.034Z.
Consensus retrieved: 2026-10-06T09:51:09.972Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T16:41:33.034Z.
Quote observation: 2026-10-06T16:40:20.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 604c485faa117edd7b478e74db8828d7312282746a460099f8cc32b45e3ebf42
Forward PE Ratio (241.57) = Dated Quote Price ($28.03) / Consensus Forward EPS ($0.12)
FORWARD PE RATIO
241.57
SECTOR MEDIAN · HEALTHCARE
19.62
median of 180 covered companies
CURRENT VS SECTOR MEDIAN
+1131.56%
vs the sector median at left
Caris Life Sciences, Inc.
Market Cap
$7.92B
Forward PE Ratio
241.57
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Caris Life Sciences, Inc. (CAI) | $7.92B | 241.57 |
| Praxis Precision Medicines, Inc. (PRAX)vs › | $7.73B | N/A |
| HealthEquity, Inc. (HQY)vs › | $7.66B | 19.39 |
| Cytokinetics, Incorporated (CYTK)vs › | $7.64B | N/A |
| Hinge Health, Inc. (HNGE)vs › | $7.60B | 42.37 |
| Oscar Health, Inc. (OSCR)vs › | $8.44B | 17.06 |
| Ionis Pharmaceuticals, Inc. (IONS)vs › | $7.34B | N/A |
| Kymera Therapeutics, Inc. (KYMR)vs › | $8.63B | N/A |
| Arrowhead Pharmaceuticals, Inc. (ARWR)vs › | $8.77B | N/A |
| Alkermes plc (ALKS)vs › | $7.01B | N/A |
Trailing P/E
78.3
reported TTM EPS
Forward P/E
241.6
consensus EPS · fiscal year ending 2026-12-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $0.12 implies -66.7% EPS decline vs the reported trailing $0.36.
At the dated quote price of $28.03, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $0.12 | $0.11 – $0.12 | 8 | 241.6x |
| 2027-12-31 | $0.34 | $0.26 – $0.42 | 8 | 81.5x |
| 2028-12-31 | $0.51 | $0.21 – $0.78 | 8 | 54.7x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
